【摘要】 ５９例难治性肺癌：３５例接受常规联合化疗无效的为组１（Ｇ１）；２４例达缓解后复发和（或）转移者为组２（Ｇ２）。异搏定（Ｖｅｒａｐａｍｉｌ，ＶＰＬ）和（或）三苯氧胺（Ｔａｍｏｘｉｆｅｎ，ＴＡＭ）始于化疗前３日，持续至化疗后４日止。ＶＰＩ及ＴＡＭ剂量各为６０～１２０ｍｇ／ｄ及６０～１２０ｍｇ／ｄ，均分３次服。原发灶区（原发灶和／或肺门淋巴结和／或纵隔、隆突淋巴结）及转移灶（胸外区域淋巴结和／或血液转移灶和／或胸膜转移或心包转移等）的ＣＲ＋ＰＲ各为４０．７％（２２／５４）及３９．８％（５１／１２８）。１～、２～、３～、４～及５～年生存率（ＳＲ）各为６９％（４１／５９）、３１％（１８／５９）、１９％（１１／５９）、７％（４／５９）及３％（２／５９）。并用耐药调变剂（ｄｒｕｇｒｅｓｉｓｔａｎｃｅｍｏｄｉｆｉｅｒ，ＲＭ）前后，１～３年ＳＲ差别显著：１２％（７／５９）与６９％（４１／５９）；８％（５／５９）与３１％（１８／５９）；３％（２／５９）及１９％（１１／５９）（Ｐ＜０．００１、＜０．０１及＜０．０５）。现存７例（２２＋～７１＋月）。ＴＡＭ＋ＶＰＬ≥３级ＷＨＯ，Ｈｂ与ＢＰＣ毒性明显高于单用ＴＡＭ者（Ｐ＜０．００１及?更多还原

【Abstract】 Based on experimental and clinical observations, it has been shown that Verapamil(VPL)or Tamoxifen (TAM) as a drug resistance modifier(RM)could partially reverse multiple drug resistance(MDR),while and TAM modulates CDDP resistance.Fifty-nine patients with refractory lung cancer were classified into two groups:35 patients with intrinsic drug-resistance(DR)as group one(G1),24 others with secondary DR as group two (G2).Drug RM was started 3 days prior to each adminstration of chemotherapy(CT)until 4 days after.The dosage was 60-120mg/day for TAM,and 360mg/day for VPL.The overall response rates(CR+PR)of the primary tumor and/or hilar nodes and/or mediastinal nodes and vs other metastatic lesions were 40.7% and 39.8% respectively.The1-,2-,3-,4-and 5-year survival rates(SR) were 69%(41/59),31%(18/59),19%(10/59)and 3.45%(2/59),respectively.Thel,2 and 3year SR of the patients before and after being given RM was 12%(7/59)vs 69%(41/59),8%(5/59) vs 31%(18/59)and 3M(2/59)vs 17%(10/59)(P<0.001,M0.01 and<0.05),respectively.Seven patients are still alive(22+-71+ months).Our results showed that TAM or/and VPL-/did partially improve the response of tumor and survival in patients with refractory lung cancer.更多还原